Yousif A. Kariri
Cell division cycle 6 (CDC6) is an independent prognostic biomarker in breast cancer
Kariri, Yousif A.; Alsaleem, Mansour; Alhatlani, Bader Y.; Al-Kawaz, Abdulbaqi; Mongan, Nigel P.; Green, Andrew R.; Rakha, Emad A.
Authors
Mansour Alsaleem
Bader Y. Alhatlani
Abdulbaqi Al-Kawaz
NIGEL MONGAN nigel.mongan@nottingham.ac.uk
Associate Pro-Vice Chancellorglobal Engagement
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Abstract
Cell division cycle 6 (CDC6) is a cell cycle protein involved in cell cycle control, DNA replication and cancer cell apoptosis. This study investigated the prognostic value of CDC6 in breast cancer (BC) utilising large well characterised cohorts of early-stages BC.
CDC6mRNA was assessed using the Molecular Taxonomy of the Breast Cancer International Consortium (n=1980), the Cancer Genome Atlas (n=854) and Kaplan–Meier Plotter (n=4,929) cohorts. CDC6 protein expression was evaluated using immunohistochemistry in a large (n=951) well-characterised Nottingham BC cohort. The associations between CDC6, clinicopathological parameters, molecular features and patient outcomes were assessed.
High CDC6 expression positively correlated with dysregulation of key BC-related genes, including gene involved in cell cycle, DNA damage repair, epithelial cell migration, and tumour microenvironment control as well as with markers characteristic of the basal-like phenotype (CK5, CK14, CK17). High CDC6 mRNA and protein expression were associated with clinicopathological parameters characteristic of aggressive behaviour, including high tumour grade, large tumour size, the presence of lymphovascular invasion and hormone receptor negativity. High CDC6 protein expression was an independent predictor of poor patients’ outcome (p=0.007; HR=1.3; 95% CI 1.2–1.9).
This study indicates that CDC6 is an independent prognostic biomarker in BC. These results warrant further functional validation for CDC6 as a potential therapeutic target in BC.
Citation
Kariri, Y. A., Alsaleem, M., Alhatlani, B. Y., Al-Kawaz, A., Mongan, N. P., Green, A. R., & Rakha, E. A. (2024). Cell division cycle 6 (CDC6) is an independent prognostic biomarker in breast cancer. Pathology, https://doi.org/10.1016/j.pathol.2024.09.006
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 16, 2024 |
Online Publication Date | Nov 14, 2024 |
Publication Date | Nov 14, 2024 |
Deposit Date | Sep 18, 2024 |
Publicly Available Date | Nov 15, 2025 |
Journal | Pathology |
Print ISSN | 0031-3025 |
Electronic ISSN | 1465-3931 |
Publisher | Lippincott, Williams & Wilkins |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1016/j.pathol.2024.09.006 |
Keywords | CDC6; breast cancer; HER2; progression; prognosis; outcome |
Public URL | https://nottingham-repository.worktribe.com/output/39720412 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0031302524002940 |
Files
This file is under embargo until Nov 15, 2025 due to copyright restrictions.
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search